Weekly Trademark Review October 30, 2012
This article was originally published in The Rose Sheet
You may also be interested in...
Koa Accel CEO Francis Duhay tells Medtech Insight what his company looks for when choosing medtech ideas to support and how his experience as a physician and inventor informs his investment strategy.
Koa Accel CEO Francis Duhay outlines his company’s plans to take some of the risk out of investing in medical device start-ups by supporting inventors with functional expertise. The Irvine, CA-based medical device accelerator is focused on start-ups that will either “fail fast” or earn a 510(k) clearance within 18 months.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.